The information below is only presented for the purposes of providing a general overview of our clinical trials. Other than where specifically noted, these compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration.

Compound

Target

Phase

COMPOUND
TARGET
PHASE
Encorafenib (LGX818)
Target: BRAF
Phase: Phase 2

Disease: BRAF-mutant non-small cell lung cancer

Sponsor: Array BioPharma

Trial Information: NCT03915951

Trial Title: An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer (PHAROS)


Encorafenib (LGX818)
Target: BRAF
Phase: Phase 2

Disease: BRAFV600-mutant melanoma brain metastasis

Sponsor: Array BioPharma

Trial Information: NCT03911869

Trial Title: An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)


Encorafenib (LGX818)
Target: BRAF
Phase: Phase 3 / registration trial

Disease: BRAFV600-mutant melanoma

Sponsor: Array BioPharma

Trial Information: NCT01909453

Trial Title: Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma (COLUMBUS)


Encorafenib (LGX818)
Target: BRAF
Phase: Phase 3 / registration trial

Disease: BRAF-mutant colorectal cancer

Sponsor: Array BioPharma

Trial Information: NCT02928224

Trial Title: Study evaluating the efficacy and safety of binimetinib, encorafenib and Erbitux in BRAFm metastatic CRC (BEACON CRC)


Encorafenib (LGX818)
Target: BRAF
Phase: Phase 2

Disease: BRAF-mutant colorectal cancer

Sponsor: Pierre Fabre

Trial Information: NCT03693170

Trial Title: Encorafenib, Binimetinib and Cetuximab in Subjects with Previously Untreated BRAF-mutant Colorectal Cancer (ANCHOR-CRC)


To learn more about encorafenib clinical trials, click here.

Binimetinib (MEK162)
Target: MEK
Phase: Phase 2

Disease: BRAF-mutant non-small cell lung cancer

Sponsor: Array BioPharma

Trial Information: NCT03915951

Trial Title: An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer (PHAROS)


Binimetinib (MEK162)
Target: MEK
Phase: Phase 2

Disease: BRAFV600-mutant melanoma brain metastasis

Sponsor: Array BioPharma

Trial Information: NCT03911869

Trial Title: An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)


Binimetinib (MEK162)
Target: MEK
Phase: Phase 3 / registration trial

Disease: BRAFV600-mutant melanoma

Sponsor: Array BioPharma

Trial Information: NCT01909453

Trial Title: Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma (COLUMBUS)


Binimetinib (MEK162)
Target: MEK
Phase: Phase 3 / registration trial

Disease: BRAF-mutant colorectal cancer

Sponsor: Array BioPharma

Trial Information: NCT02928224

Trial Title: Study evaluating the efficacy and safety of binimetinib, encorafenib and Erbitux in BRAFm metastatic CRC (BEACON CRC)


Binimetinib (MEK162)
Target: MEK
Phase: Phase 2

Disease: BRAF-mutant colorectal cancer

Sponsor: Pierre Fabre

Trial Information: NCT03693170

Trial Title: Encorafenib, Binimetinib and Cetuximab in Subjects with Previously Untreated BRAF-mutant Colorectal Cancer (ANCHOR-CRC)


To learn more about binimetinib clinical trials, click here.

Larotrectinib
Target: Trk family

Disease: Cancer

To learn more about larotrectinib clinical trials, click here.

Danoprevir
Target: NS3 Protease

Disease: Hepatitis C

To learn more about danoprevir clinical trials, click here.

Selumetinib (AZD6244)
Target: MEK
Phase: Phase 2

Disease: Neurofibromatosis Type 1

Sponsor: National Cancer Institute

Trial Information: NCT01362803

Trial Title: AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors


To learn more about selumetinib clinical trials, click here.

Tucatinib (ONT-380)
Target: HER2

Disease: Breast cancer

To learn more about tucatinib clinical trials, click here.

Ipatasertib / GDC-0068
Target: AKT

Disease: Solid tumors

To learn more about ipatasertib clinical trials, click here.

Varlitinib (ASLAN001)
Target: Pan-HER

Disease: Cancer

To learn more about varlitinib clinical trials, click here.

ARRY-797 (ARRY-371797)
Target: p38
Phase: Phase 3 / registration trial

Disease: LMNA-related dilated cardiomyopathy

Sponsor: Array BioPharma

Trial Information: NCT03439514

Trial Title: A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation


To learn more about ARRY-797 clinical trials, please call 303.381.6604 or click here.

LOXO-292
Target: Ret

Disease: Cancer

To learn more about LOXO-292 clinical trials, click here.

ARRY-382 / CSF1R
Target: CSF1R
Phase: Phase 2

Disease: Solid tumors

Sponsor: Array BioPharma

Trial Information: NCT02880371

Trial Title: A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors


To learn more about ARRY-382 clinical trials, click here.

Motolimod / VTX2337
Target: Toll-like Receptor

Disease: Cancer

To learn more about motolimod clinical trials, click here.

LOXO-195
Target: Trk family

Disease: Cancer

To learn more about LOXO-195 clinical trials, click here.

No results found

Try removing filter choices or click here or click the Reset button to view the full clinical trials.